Literature DB >> 18541513

[Dual effects of androgens on mammary gland].

Jean-Philippe Brettes1, Carole Mathelin.   

Abstract

Androgens have a dual effect on mammary cells. Indeed, they have an influence on mammary cells proliferation thanks to several possible mechanisms, including their transformation into dihydrotestosterone (5alpha-reductase pathway) or into estradiol (aromatase pathway) or their binding to the androgen receptor (AR) and/or to the estrogen receptor (ER). Androgen signaling, using 5alpha-reductase pathway, enables the control of cell proliferation, mediated by AR. So androgen signaling plays a crucial role in breast homeostasis, negating the proliferative effects of estrogen signaling in the breast. When androgens transform into estrogens (aromatase pathway), they increase cell proliferation and mammary carcinogenesis risk. High levels of androgens and estrogens in the serum are associated with increased incidence of postmenopausal breast cancers. Genetic variations in metabolic genes (CYP11, CYP19) and in the AR gene are both involved in dual effects of androgens. Since mammary cells metabolic enzymes vary with time, aging increases the risk of breast cancer induced by estrogens and androgens. In addition, AR function can be perturbed by low doses of synthetic progestin, acting as endocrine disruptors to negate the protective effects of androgen signaling in the breast. In the future, the determination of AR expression in infiltrative breast cancer specimens and circulating androgens levels could provide additional information about hormonal dependency and prognosis of breast carcinomas.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18541513     DOI: 10.1684/bdc.2008.0631

Source DB:  PubMed          Journal:  Bull Cancer        ISSN: 0007-4551            Impact factor:   1.276


  5 in total

1.  Sex hormone levels and risks of estrogen receptor-negative and estrogen receptor-positive breast cancers.

Authors:  Ghada N Farhat; Steven R Cummings; Rowan T Chlebowski; Neeta Parimi; Jane A Cauley; Thomas E Rohan; Alison J Huang; Mara Vitolins; F Allan Hubbell; Joann E Manson; Barbara B Cochrane; Dorothy S Lane; Jennifer S Lee
Journal:  J Natl Cancer Inst       Date:  2011-02-17       Impact factor: 13.506

2.  Potential prognostic value of the lymph node ratio and its correlation with circulating sex hormone concentration in pathological T1/2 breast cancer patients: a retrospective study.

Authors:  Wangyu Zhu; Xia Qiu; Nawa Lin; Kexin Fang; Tinglei Zhang; Naohiro Ishii; Warren Matthew Rozen; Alireza Hamidian Jahromi; Jian Huang
Journal:  Ann Transl Med       Date:  2022-05

3.  Postmenopausal plasma sex hormone levels and breast cancer risk over 20 years of follow-up.

Authors:  Xuehong Zhang; Shelley S Tworoger; A Heather Eliassen; Susan E Hankinson
Journal:  Breast Cancer Res Treat       Date:  2013-01-03       Impact factor: 4.872

4.  Identification of functional consequence of a novel selection signature in CYP11b1 gene for milk fat content in Bubalus bubalis.

Authors:  J Maryam; Masroor Ellahi Babar; Asif Nadeem; Tahir Yaqub; Abu Saeed Hashmi
Journal:  Meta Gene       Date:  2015-10-22

5.  Breast malignancy in female-to-male transsexuals: systematic review, case report, and recommendations for screening.

Authors:  Anne C Fledderus; H Antoine Gout; Aernout C Ogilvie; Dorothea K G van Loenen
Journal:  Breast       Date:  2020-07-02       Impact factor: 4.380

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.